BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, August 1, 2026
Home » Topics » Monoclonal antibody, BioWorld Science

Monoclonal antibody, BioWorld Science
Monoclonal antibody, BioWorld Science RSS Feed RSS

Illustration of monoclonal antibody hovering between doctor's hands
Nephrology

Climb Bio licenses anti-APRIL monoclonal antibody from Mabworks

Jan. 10, 2025
Climb Bio Inc. has entered into an exclusive license agreement with Beijing Mabworks Biotech Co. Ltd. for rights to develop and commercialize MIL-116 (now CLYM-116), an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy, in the territory outside of Greater China.
Read More
Monoclonal antibody illustration
Cancer

177Lu-RAD-202 approved for therapeutic phase I in Australia

Dec. 23, 2024
Radiopharm Theranostics Ltd. has been granted Belberry Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human phase I therapeutic study of 177Lu-labeled RAD-202 (177Lu-RAD-202) for the treatment of HER2-expressing solid tumors, including breast and gastric cancers.
Read More
Immuno-oncology

Funding supports Tigatx’s engineered IgA platform for cancer and infectious disease

Dec. 19, 2024
Tigatx Inc. has been awarded up to $33.5 million in funding by the Advanced Research Projects Agency for Health and a 2-year $2 million Direct to Phase II Small Business Innovation Research grant from the National Cancer Institute.
Read More
3D illustration of the cross-section of skin layers with atopic dermatitis
Dermatologic

Astria’s OX40 antagonist gains US IND clearance for atopic dermatitis

Dec. 11, 2024
Astria Therapeutics Inc. has gained IND clearance from the FDA for STAR-0310, a monoclonal antibody OX40 antagonist being developed for atopic dermatitis.
Read More
Immuno-oncology

Notch1 specific antibody has promise in melanoma solo, as combo

Dec. 9, 2024
Researchers have developed an anti-Notch1 monoclonal antibody.
Read More
Immuno-oncology

Anti-ADAM10 mAb prolongs survival in preclinical models of high-grade glioma

Dec. 3, 2024
Researchers from Memorial Sloan Kettering Cancer Center and affiliated organizations revealed findings from the preclinical evaluation of 1H5, a novel monoclonal antibody (mAb) candidate that inhibits the NOTCH signaling pathway and is being developed for the treatment of high-grade gliomas (HGGs).
Read More
Immune

Seed funding at Autoimmunity Biosolutions to advance immuno-corrective therapy for autoimmune diseases

Nov. 22, 2024
Autoimmunity Biosolutions has closed a seed financing to support its work advancing a next-generation, immuno-corrective therapy for autoimmune diseases. The company’s approach targets a branch of the interleukin-7 (IL-7)/interleukin-7 receptor (IL-7R) pathway controlled by the soluble IL-7R (sIL-7R), a critical amplifier of autoimmune reactions.
Read More
Illustration of monoclonal antibody hovering between doctor's hands
Immuno-oncology

Chugai designs mAb to target latent TGF-β1 activation

Nov. 13, 2024
Chugai Pharmaceutical Co. Ltd. has generated a monoclonal antibody targeting latent TGF-β1 for cancer immunotherapy.
Read More
Monoclonal antibody illustration
Inflammatory

Hifibio Therapeutics’ BTLA agonist antibody gains US IND clearance

Nov. 5, 2024
Hifibio Therapeutics Inc. has gained IND clearance from the FDA for HFB-200604, a potentially best-in-class BTLA agonist monoclonal antibody for inflammatory and immunology diseases.
Read More
Infection

Siga Technologies exercises option to license orthopoxvirus monoclonal antibodies from Vanderbilt University

Oct. 23, 2024
Siga Technologies Inc. has entered into an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclonal antibodies (MAbs) which could be used as potential treatments for a broad range of orthopoxviruses, including smallpox and mpox.
Read More
Previous 1 2 … 5 6 7 8 9 10 11 12 13 … 19 20 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 31, 2026.
  • Illustration of dopamine signaling in the brain

    New schizophrenia targets challenge trial design

    BioWorld
    The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 28, 2026
  • HIV virus

    AIDS 2026: New targets for metabolic dysfunction despite ART

    BioWorld
    Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
  • Lee-Cheng Liu, chairman, Taiwan BIO

    Taiwan biotech looks outward in next phase of growth

    BioWorld
    Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing